|
Issue |
Title |
|
No 15 (2020) |
Functional gall-bladder disorders and non-alcoholic fatty liver disease: clinical features and new approaches to therapy |
Abstract
PDF (Rus)
|
S. N. Mekhtiev, O. A. Mekhtieva, Z. M. Ibragimova |
|
No 15 (2020) |
Possibilities of ademetionine in treatment of patients with alcoholic liver disease |
Abstract
PDF (Rus)
|
L. V. Maslovskiy, M. I. Bulanova, O. F. Shaposhnikova, O. N. Minushkin |
|
No 15 (2020) |
Current international guidelines for the management of patients with chronic viral hepatitis C |
Abstract
PDF (Rus)
|
Ju. L. Tonkikh, A. V. Vasyutin, V. V. Tsukanov |
|
No 15 (2020) |
Bicyclol in the treatment of patients with chronic diffuse liver diseases |
Abstract
PDF (Rus)
|
M. V. Maevskaya, V. D. Lunkov, N. I. Geyvandova, L. K. Palgova, I. Yu. Pirogova, M. K. Prashnova, N. V. Marchenko, E. N. Zinovieva, T. A. Ilchishina, V. T. Ivashkin, P. V. Koroy |
|
No 15 (2020) |
Sphincter of Oddi dysfunction in the post-cholecystectomy period |
Abstract
PDF (Rus)
|
A. О. Bueverov |
|
No 15 (2020) |
Combined herbal medicine for chronic alcoholic liver disease |
Abstract
PDF (Rus)
|
V. V. Skvortsov, M. V. Lunkov, М. V. Levitan |
|
No 5 (2020) |
Possibilities of application of enterosorbent in combined therapy of opistorchosis patients with skin syndrome |
Abstract
PDF (Rus)
|
V. V. Tsukanov, A. V. Vasyutin, J. L. Tonkikh, E. G. Gorchilova, O. S. Rzhavicheva, А. G. Borisov |
|
No 5 (2020) |
Ursodeoxycholic acid and its unexpected application areas |
Abstract
PDF (Rus)
|
A. R. Reyzis |
|
No 5 (2020) |
Role of human albumin in the management of liver cirrhosis |
Abstract
PDF (Rus)
|
M. V. Maevskaya, M. S. Zharkova |
|
No 5 (2020) |
Prevention options of toxic drug-induced liver disease in patients with chemotherapy of oncological diseases |
Abstract
PDF (Rus)
|
E. I. Bezvulyak, V. A. Basharin, A. V. Epifantsev, V. P. Kutsenko, P. V. Seliverstov |
|
No 5 (2020) |
Alcoholic liver disease. Clinical example |
Abstract
PDF (Rus)
|
T. E. Polunina |
|
No 14 (2019) |
Ursodeoxycholic acid and cancer prevention |
Abstract
PDF (Rus)
|
A. R. Reyzis |
|
No 14 (2019) |
Treatment Options for Patients with Gallstones (Cholelithiasis) |
Abstract
PDF (Rus)
|
P. V. Seliverstov, T. E. Skvortsova, S. I. Sitkin, V. G. Radchenko |
|
No 14 (2019) |
Evaluation of the effectiveness of the drug Samelix in patients with cholestasis in chronic alcoholic liver disease |
Abstract
PDF (Rus)
|
O. N. Minushkin, L. V. Maslovsky, M. I. Bulanova, O. F. Shaposhnikovа |
|
No 14 (2019) |
Functional activity of blood phagocytes in opistorchiasis patients |
Abstract
PDF (Rus)
|
E. G. Gorchilova, O. A. Kolenchukova, I. I. Gvozdev, A. A. Savchenko, A. V. Vasyutin, Yu. L. Tonkikh, A. G. Borisov, O. S. Rzhavicheva, V. V. Tsukanov |
|
No 14 (2019) |
Alcoholic liver disease: a modern look at diagnosis and treatment |
Abstract
PDF (Rus)
|
R. G. Myazin, D. N. Emel’yanov |
|
No 14 (2019) |
Cholestasis syndrome in a comorbid patient: diagnostic difficulties |
Abstract
PDF (Rus)
|
E. V. Vinnitskaya, T. Yu. Khaymenova, K. G. Saliev, E. S. Skibkina, K. G. Absandze, Yu. G. Sandler |
|
No 3 (2019) |
Primary biliary cholangitis – a new nosological unit in the classification of liver diseases (literature review and own clinical observation) |
Abstract
PDF (Rus)
|
T. V. Penkina, E. A. Shikina, D. T. Dicheva, O. E. Berezutskaya, N. L. Golovkina, L. G. Bektemirova, D. N. Andreev, S. A. Karaulov |
|
No 3 (2019) |
Multi-component infusion hepatoprotectors for liver damage |
Abstract
PDF (Rus)
|
E. I. Sas, V. B. Grinevich |
|
No 3 (2019) |
Safety profile of pharmacotherapy in paitionts with non-alcogolic fatty liver disease |
Abstract
PDF (Rus)
|
E. I. Peresada, P. V. Seliverstov, T. V. Vavilova, V. A. Basharin, V. G. Radchenko |
|
No 14 (2018) |
Different types of hyperammonemia in clinical practice |
Abstract
PDF (Rus)
|
E. Yu. Plotnikova, A. S. Sukhikh |
|
No 3 (2018) |
Hepatic encephalopathy: features of pharmacotherapy |
Abstract
PDF (Rus)
|
A. V. Polukhina, T. Yu. Khaimenova, E. V. Vinnitskaya |
|
No 3 (2018) |
Experience of using ademethionin in treatment of patients with non-alcoholic fatty liver disease |
Abstract
PDF (Rus)
|
L. A. Zvenigorodskaya |
|
No 3 (2018) |
Efficacy of ursodezoxycolic acid in the treatment of non-alcoholic fatty liver disease |
Abstract
PDF (Rus)
|
D. T. Dicheva, E. I. Kuznetsova, T. A. Baeva |
|
No 15 (2017) |
MODERN ASPECTS OF TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE |
Abstract
PDF (Rus)
|
R. G. Myazin |
|
No 15 (2017) |
ПЕЧЕНЬ – ВАЖНЫЙ ОРГАН КАК СОХРАНИТЬ ЕЕ ЗДОРОВОЙ? |
Abstract
PDF (Rus)
|
|
|
No 14 (2016) |
Эволюционный путь в лечении гепатита С |
Abstract
PDF (Rus)
|
I. G. Bakulin, Yu. Cherednichenko |
|
No 14 (2016) |
Difficulties in establishment of celiac syndrome diagnosis |
Abstract
PDF (Rus)
|
M. F. Osipenko, E. V. Shreiner |
|
No 14 (2016) |
Hepatoprotectors of vegetable origin in therapy of drug-induced hepatitis |
Abstract
PDF (Rus)
|
O. N. Minushkin, I. V. Zverkov, A. I. Ostrovskaya |
|
No 14 (2016) |
Hepatoprotectors in the therapy of some hepatic diseases |
Abstract
PDF (Rus)
|
O. N. Minushkin |
|
No 14 (2016) |
Possibilities of essential phospholipids in alcoholic liver disease of terminal stage |
Abstract
PDF (Rus)
|
M. A. Butov, A. S. Vasilevskaya |
|
No 14 (2016) |
Polynosological effects of ursodeoxycholic acid (UDCA). Practice of using |
Abstract
PDF (Rus)
|
V. M. Makhov, T. V. Volodina, A. S. Panferov, T. V. Turko |
|
No 14 (2016) |
Experience of therapy of chronic viral hepatitis c patients with unfavourable response predictors |
Abstract
PDF (Rus)
|
N. I. Geyvandova, A. V. Lipov, P. V. Koroy, A. V. Yagoda, S. S. Rogova |
|
No 14 (2016) |
Sofosbuvir in therapy of chronic HCV-infection |
Abstract
PDF (Rus)
|
C. S. Pavlov, Y. O. Shulpekova, N. V. Shulpekova, M. C. Semenistaya, A. A. Usanova |
|
No 14 (2016) |
Hepatic encephalopathy syndrome: current aspects of diagnosis and treatment |
Abstract
PDF (Rus)
|
D. I. Trukhan |
|
1 - 35 of 35 Items |
|